UK-based clinical genomics interpretation software provider Congenica has partnered with Irish SFI Research Centre FutureNeuro to develop new software for quick and accurate detection of genetic epilepsies.
The new software will use electronic health record (EHR) systems to ensure that clinicians and patients will be able to access the complete diagnostic process through their digital records.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
To be based on Congenica’s clinical genomics analysis software called Sapientia, the research will be carried out at the FutureNeuro Human Genetics lab in Dublin, Ireland.
The new tool, which examines the structure, function, mapping, and editing of genomes on a molecular level, is intended to facilitate tailored treatment decisions and improve therapy options for some types of genetic epilepsy.
FutureNeuro clinical neurologist Dr Norman Delanty said: “Genomics is changing clinical medicine.
“Neurologists need to embrace it as a new powerful diagnostic tool to allow us to understand the many challenging faces of epilepsy, and lead us to individualising treatment and prognosis in the clinic.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDuring the initial stages of the partnership, the diagnostic potential of Sapientia for epilepsy will be advanced by linking the software’s knowledgebase of epilepsy data to genetic sequencing activities within FutureNeuro.
Congenica CEO Dr David Atkins said: “The types of genetic mutations that this project will focus on are thought to be at the root of as much as 40% of childhood epilepsy.”
Through the partnership, the firms plan to provide better insights into the causes of various epilepsies and accelerate the combination of genomics and electronic health records.
